Placebo-controlled trials

In low doses, inhaled NO may have a beneficial therapeutic effect, since NO in the inspired air leads to pulmonary vasodilation. In persistent pulmonary hypertension of the newborn, NO inhalation has already been used with some success. NO inhalation as the treatment for acute respiratory distress syndrome, however, has been disappointing. Only transient improvements of oxygenation were detected and the outcome of placebo-controlled trials did not show any improvement... [Pg.575]

Dorus and colleagues (1989) conducted a multicenter, double-blind, placebo-controlled trial in depressed and nondepressed alcoholic veterans. A total of 457 male alcoholic patients, of whom approximately one-third were depressed, were randomly assigned to receive either 600-1,200 mg/day of lithium or a comparable number of placebo capsules. No significant differ-... [Pg.38]

Fawcett J, Clark DC, Aagesen CA, et al A double-blind, placebo-controlled trial of lithium carbonate therapy for alcoholism. Arch Gen Psychiatry 44 248-2 56,1987... [Pg.44]

Kranzler HR, Del Boca F, Korner P, et ah Adverse effects limit the usefulness of flu-voxamine for the treatment of alcoholism.] Subst Abuse Treat 10 283-287, 1993 Kranzler HR, Burleson JA, Del Boca FK, et ah Buspirone treatment of anxious alcoholics a placebo-controlled trial. Arch Gen Psychiatry 31 720—731, 1994 Kranzler HR, Burleson JA, Korner P, et ah Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics. Am] Psychiatry 152 391-397, 1995 Kranzler HR, Burleson JA, Brown J, et al Fluoxetine treatment seems to reduce the beneficial effects of cognitive-behavioral therapy in type B alcoholics. Alcohol Clin Exp Res 20 1534-1341, 1996... [Pg.48]

Malcolm R, Anton RF, Randall CL, et al A placebo-controlled trial of Buspirone in anxious inpatient alcoholics. Alcohol Clin Exp Res 16 1007—1013, 1992... [Pg.49]

McRae AL, Sonne SC, Brady KT, et al A randomized, placebo-controlled trial of buspirone for the treatment of anxiety in opioid-dependent individuals. Am J Addict 13 53-63, 2004... [Pg.104]

Nestler EJ, Hyman SE, Malenka RC Molecular Neuropharmacology A Foundation for Clinical Neuroscience. New York, McGraw Hill, 2001 Novick DM, Pascarelli EE, Joseph H, et al Methadone maintenance patients in general medical practice a preliminary report. JAMA 259 3299—3302, 1988 Nunes EV, Quitkin EM, Donovan SJ, et al. Imipramine treatment of opiate-dependent patients with depressive disorders a placebo-controlled trial. Arch Gen Psychiatry 55 153-160, 1998... [Pg.105]

Cornelius JR, Salloum IM, EhlerJG, et al Fluoxetine in depressed alcoholics a doubleblind, placebo-controlled trial. Arch Gen Psychiatry 54 700—705, 1997 Cornelius JR, Salloum IM, Haskett RF, et al Fluoxetine versus placebo for the marijuana use of depressed alcoholics. Addict Behav 24 111—114, 1999 Cui S-S, Bowen RC, Gu G-B, et al Prevention of cannabinoid withdrawal syndrome by lithium involvement of oxytocinergic neuronal activation. J Neurosci 21 9867— 9876, 2001... [Pg.177]

Catecholamine Reserpine, propranolol, and other p blockers Placebo-controlled trial of reserpine had negative... [Pg.196]

Kranzler HR, Bauer LO, Hersh D, et al Carbamazepine treatment of cocaine dependence a placebo-controlled trial. Drug Alcohol Depend 38 203-211, 1995 Levin FR, Lehman AF Meta-analysis of desipramine an adjunct in the treatment of cocaine addiction. J Clin Pharmacol 11 374-378, 1991 Lima MS, Reisser AA, Soares BG, et al Antidepressants for cocaine dependence. Cochrane Database Syst Rev 4 CD002950, 2001 Ling W, Shoptaw S, Majewska D Baclofen as a cocaine anti-craving medication a preliminary clinical study 0etter). Neuropsychopharmacology 18 403 04, 1998... [Pg.206]

Covey LS, Classman AH A meta-analysis of double-blind placebo controlled trials of clonidine for smoking cessation. Br J Addict 86 991—998, 1991 Covey LS, Classman AH, Stetner F Naltrexone effects on short-term and long-term smoking cessation.] Addict Dis 18 31 0, 1999 Covey LS, Sullivan MA, Johnston A, et al Advances in non-nicotine pharmacotherapy for smoking cessation. Drugs 39 17-31, 2000 Dani JA, De Biasi M Cellular mechanisms of nicotine addiction. Pharmacol Biochem Behav 70 439 46, 2001... [Pg.335]

Schneider NG, Olmstead RE, Steinberg C, et al Efficacy of buspirone in smoking cessation a placebo-controlled trial. Clin Pharmacol Ther 60 568-575, 1996 Shiffman S, Dresler CM, Hajek P, et al Efficacy of a nicotine lozenge for smoking cessation. Arch Intern Med 162 1267-76, 2002... [Pg.337]

Anton RF, Moak DH, Waid LR, et al Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics results of a placebo-controlled trial. Am J Psychiatry 156 1758—1764, 1999... [Pg.357]

Gruzdev B, Rakhmanova A, Doubovskaya E, Yakovlev A, Peelers M, Rinehart A, de Dier K, Baede-van Dijk B, Parys W, van t Klooster G (2003) A randomized, double-bhnd, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral n Ve, HIV-1 infected subjects. AIDS 17 2487-2494... [Pg.172]

Berger J, Ring J Efficacy of antihistamine pretreat- 15 ment in the prevention of adverse reactions to Hymenoptera venom immunotherapy a prospective randomized placebo-controlled trial. J Allergy 16 Clin Immunol 1997 100 458-463. [Pg.10]

Rogers SL, Friedhoff LT (1996). The efficacy and safety of Donepezil in patients with Alzheimer s disease results of a US multicentre, randomised, double-blind, placebo-controlled trial. Dementia ,... [Pg.87]

Simpson DM, Olney R et al (2000) A placebo-controlled trial of lamotrigine for painful HIV-associated neuropathy. Neurology 54(11) 2115-2119 Simpson DM, Katzenstein D et al (2001) Plasma carnitine in HIV-associated neuropathy. AIDS 15(16) 2207-2208... [Pg.84]

The current use of IV rt-PA for acute stroke thrombolysis is based on the NINDS rt-PA study, a two-part randomized, double blind, placebo-controlled trial. " This trial was preceded by two open-label, dose-escalation safety studies that suggested that treatment within 180 minutes of stroke onset, and rt-PA dosages no higher than 0.95 mg/kg, was safe and effective. ... [Pg.42]

E, Davis S, Donnan G, Schneider D, Diez-Tejedor E, Trouillas R Randomised double-blind placebo-controlled trial of thrombol3ffic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet. 1998 352 1245-1251. [Pg.57]

Middle Cerebral Artery Occlusion and the PROACT Trial The safety and efficacy of lAT in the anterior circulation have been evaluated in two randomized, multicenter, placebo-controlled trials. In the Prolyse in Acute Cerebral Thromboembolism (PROACT) 1 and 11 trials, patients with proximal MCA (Ml or M2 segment) occlusions within 6 hours of symptom onset were treated with recombinant prourokinase (r-pro-UK) or placebo. ... [Pg.66]

Microplasmin is a truncated form of plasmin that is more resistant to the effects of antiplasmin. In a rabbit stroke model, intravenous microplasmin infusion resulted in a high rate of clot lysis without increasing the rate of ICH. In addition, there was significant improvement in the behavioral rating scores, suggesting a neu-roprotective effect. The ongoing MITI-IV trial is a 40-patient multicenter, double-blind, placebo-controlled trial using three different intravenous doses of microplas-min to treat acute ischemic stroke (NIHSS >6 and <22) within 12 hours of symptom onset. [Pg.77]

Lodder J, van Raak L, Hilton A, Hardy E, Kessels A. Diazepam to improve acute stroke outcome results of the early gaba-ergic activation study in stroke trial. A randomized double-blind placebo-controlled trial. Cerebrovasc Dis 2006 21 120-127. [Pg.115]

Tseng MY, Czosnyka M, Richards H, Pickard JD, Kirkpatrick PJ. Effects of acute treatment with pravastatin on cerebral vasospasm, autoregulation, and delayed ischemic deficits after aneurysmal subarachnoid hemorrhage a phase II randomized placebo-controlled trial. Stroke 2005 36 1627-1632. [Pg.116]

Placebo-Controlled Trials ofUFH, LMWH, and Heparinoids The International Stroke Trial (1ST) was a randomized, placebo-controlled trial of UFH (5000 or 12,500 lU twice daily) and aspirin (300 mg) in 19,435 unselected patients with acute stroke within 48 hours of symptom onset. Because of limited availability of neuroimaging, 33% of participants were enrolled with suspected but not proven ischemic stroke, some of whom may have suffered primary intracerebral hemorrhage (ICH). [Pg.139]

The Trial of Org 10172 in Acute Stroke Treatment (TOAST) was a randomized, double-blind, placebo-controlled trial of danaparoid in 1281 patients within 24 hours of onset of acute ischemic stroke. A three-stage dosage regime was used to achieve plasma anti-factor Xa activity of 0.8 unit/mL. Favorable outcome was defined as the combination of a Glasgow Outcome Scale (GOS) score of 1 or 2 and a modified Barthel Index (BI) score of 12 or greater (on a scale of 0-20) at 3 months or 7 days. Very favorable outcome required the combination of a GOS score of 1 and a Barthel Index (BI) score of 19 or 20 at 3 months or 7 days. [Pg.140]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...